DANYELZA® (naxitamab)
Neuroblastoma
ApprovedActive
Key Facts
About SERB Pharmaceuticals
SERB Pharmaceuticals is a Belgium-based, global specialty pharma company with a dual focus on emergency medicine (antidotes/CBRN) and rare diseases. Founded in 2008 but tracing its heritage to the 1950s, SERB has built a fully integrated commercial platform, directly selling in 18 countries and supplying over 100. The company is in a clear growth phase, evidenced by strategic acquisitions like Y-mAbs Therapeutics, high-profile leadership appointments, and a pipeline leveraging its antibody platform, positioning it as a critical supplier to healthcare systems and governments worldwide.
View full company profileOther Neuroblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Neuroblastoma Risk Stratification | Quibim | Research |
| VNX-201 | Vironexis Biotherapeutics | Preclinical |
| GD2-GD3 Bispecific Vaccine | Y-mAbs Therapeutics | Early Clinical |